PharmaShots | Incisive News in 3 Shots

Subscribe Now

nmibc

The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

August 16, 2021

Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

Merck's Keytruda (pembrolizumab) Receives FDA's Priority Review for sBLA to Treat High-Risk Non-Muscle Invasive Bladder Cancer (NM...

December 2, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us